Pharmaceuticals, Biotechnology and Life Sciences
Ipsen has acquired global oncology assets from Merrimack Pharmaceuticals. This acquisition includes Merrimack’s key marketed product Onivyde (irinotecan liposome injection)…
e-Therapeutics plc, the drug discovery company, has made further steps in transitioning its business as it picked Amgen Inc.’s Corporate Development Executive Director, Dr. Raymond Barlow as its new Chief Executive Officer (CEO) who assume his position before May 1, 2017.
AB Sciences has more reasons to believe that its protein kinase inhibitor (PKI) masitinib could have FDA’s further clearence, as the results from the pivotal phase 3 study have been published in highly regarded independent general medical journal, The Lancet.
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.
Novartis and Ionis Pharmaceuticals with its affiliate Akcea Therapeutics have signed an agreement for licensing two novel treatments for reducing cardiovascular risk in patients with high levels of lipoproteins known as Lp(a) and ApoCIII.
Sanofi and Regeneron Pharmaceuticals are going to will appeal the injunction granted on Friday by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent in the U.S. during the term of two Amgen patents.
Shield Therapeutics said it was encouraged by the the demand of its its recently approved product for the treatment of iron…
Georgia Healthcare Group (GHG) has finished all the paperwork in connection with buying the fourth largest pharmaceutical retailer in Georgia, ABC Pharmacia (ABC).
Indian drugmaker Natco Pharma has gotten the approval from the U.S. regulator for generic version of Teva’s leukemia treatment Trenda (Bendamustine Hydrochloride powder for Injection).
Eli Lilly begins new year with reorganizing its leadership structure to pursue better growth opportunities in the upcoming years. The Chief Executive Officer of Lilly, David A. Ricks, who’s new position is also one among the latest promotions, said that the changes made to pharmaceutical therapeutics and geographic business should simplify and maximize the company’s late-stage pipeline and new drugs, as well as to improve productivity.